DOCSLIB.ORG

Log Mescaline and Lysergic Acid Diethylamide: Therapeutic Implications of the Drug-Induced State

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Log Mescaline and Lysergic Acid Diethylamide: Therapeutic Implications of the Drug-Induced State j. t, Dis.nerv.Syst. 30, Suppl. No. 2, 23-27 (1969). LSD 1797 ,l.'agoo:g Mescaline and Lysergic Acid Diethylamide: Therapeutic Implications of the Drug-Induced State :oxic- P.E. HERMAN C.B. DENBER, M.D., Ph.D. )Zog/c :ago: *'I voas persuaded that by using such drugs one thylamide s_3, and mescaline _'ls. It is generally ¢ei_tl penetrate into the cavernous darkness of agreed that the effects of these two drugs are f po- _a$ illness and come to the ultimate hidde_t similar, with perhaps some minor variations of and ca_ue of these many stra_ge and different i//- a pharmacological and clinical nature _7. Their Drug _ which _j custom have come to be desig- relationship to the schizophrenic psychosis is _ork: hated as "madness". ' disputed _s, although KeeleV 9 maintains a re- So wrote Joseph Moreau de Tours in 1845 _,2 semblance does exist between them. Our studies ating _ in regard to his experimental studies with are in agreement with the latter. tal to ', hashish. He emphasized that experiencing the t-380, , dr_-induced psychotic-like syndrome could Clinical ' lead to insight regarding the patient's illness. While there is a similarity between reac- dif- Some inferences of his work, described in a tions of normal, neurotic or psychotic subjects .-ugs::250- pilpar submitted to the Academic des Sciences to both drugs, the psychotic patients tend to , of Paris for the Prix Montyon in 1845, were show a greater disorganization of thought. ,logic _ criticized by the committee who said, "unfor- Schizophrenic patients in remission will have , 26_ .tunately, the facts related to the therapeutic a recrudescence of their psychosis under use of hashish are insufficient to allow one to mescaline or lysergic acid diethylamide which draw any conclusions whose practical applica- is difficult to distinguish from the endogenous tions would be incontestable". One hundred and disorder. Artists, writers and others occasion- twenty-three years later, the situation has ally have a vivid reaction, sometimes described changed little in regard to the therapeutic ad- as leading to a profound "transcendental ex- ministration of drugs capable of producing perience". The drug accentuates the basic per- states resembling naturally occurring mental sonality pattern and has been used in some in- dimrders, stances as a diagnostic tooF °. At the present time, the use of pharmaco- The following refers to the effects of an in- l_gic compounds which can experimentally in- travenous i_jection of 500 mg. of mescaline d_ce a condition of disordered feeling or think- in hospitalized psychiatric patients, based on a hag is considered to be fraught with much dan- comprehensive study of 350 patients. Within ger s'e. GrinkeV gives the ultimate view that ten minutes (although when given orally it is "[he drugs are indeed dangerous even when much slower), a series of symptoms appeared: t used under the best of precautions and condi- Tachycardia, hypertension (hypotension also i tiqms". Restrictive regulations in many coun- may occur), mydriasis, marked anxiety, ten- i t_ concerning the experimental use of so- sion, sensations of hot and cold (frequently calk_ "hallucinogenic" drugs threatens to re- in the genital area), retching, vomiting, pep- talM and finally inhibit further research in permint taste in the mouth, choking, constric- hh_ areas. Science requires a more sober ap- tion of the chest and hyperpnea. The skin may Inrush to the problem and such is the purpose show color changes, occasionally becoming cold efthis brief review, and blanched. A desire to defecate or urinate i J Much interest has been centered on reports was expressed, although rarely necessary. economy was met by a riddance mechanism -- ii of therapeutic activity for lysergic acid die- An external threat to the organism's inner " _f lB_ea_'ch Division, iVfanhattan State Hospital, the desire to urinate, defecate or expectorate. i_ Wlut_s Island, New York, N.Y. 10035. This took place almost immediately after the t; 23 t I-IERI_IANC.B.DENBER injection began, before it was terminated, and and space are described. Some patients ap- t before any- real psychologic response had taken peared to be living through a dreamy ecstatic occu place. This reaction would seem to indicate that state, undergoing an extraordinary inner ex- prok "flight" occurs before "fight", is unconscious perience with very little external display. It in c_ and might even be instinctive. Flight would would be as if they had retreated "within" ' whir appear to be more primitive of the two reac- where they and the world were the same. pro}. tions, with fight being only a later possible cot- Symbolic acting-out with gesturing is very '- leas1 tieal addition. This would suggest perhaps an common; recognition of these displays is most cone instinctual response which is present even in helpful in understanding similar phenomena horn the most primitive forms who attempt to rid from a psychodynamic point of view. Women itial themselves of noxious or poisonous agents-_k may fantasy parturition even though never any Some patients screamed, "I'm going crazy, previously pregnant. Transference feelings '- Tpenhisdingstuffdoommakesis occasionallyme crazy". verbalized.A feeling ofTheseim- withmarked.acting-outAggressiveto theand psychiatristhostile impulareses veryare i_ ._ s._nmptoms recede within ten minutes as the released, directed outwardly in either a random, _, , of v patient becomes increasingly fearful, suspi- diffuse fashion or towards an individual -- fre- '_ resp. cious, hostile, antagonistic and apprehensive, quently the psychiatrist, who then becomes a _ The, looking about furtively in the room and walk- symbol of feelings towards the patient's signi- ' ease: ing restlessly, ficant environmental figures (usually the par- r , still One of three events can occur between 20- ents). The physician reminded one patient of a var_ 30 minutes after the onset: a) anxiety in- her father, "He used to lock me in the room motiv creases vertically and the patient is in the grips and I'd scream and bang on the door. I hate treatr of an intense panic state which dominates the you like I hated him". In this ease, the pa- action clinical picture, b) the autonomic reaction dis- tient was referring to the treatment room door .- state_. appears as the patient rests quietly and is which was locked. These potentially destrue- revie_ withdrawn for the duration of the drug-in- tive impulses were accompanied by an intense , wider duced state, or c) anxiety decreases and symp- affeetive discharge. .* addict toms appear. Childhood memories are reactivated and re- uals, combination.The symptomsAn acusuteuallypanicappearedreaction alonecan occuror in lived with intense and extraordinary clarity, , , furth, whithe lepicture., on the Whenother nausea,hand, mutismretchingmayanddominatevomit- athoughtsccompaniedand byfeelingssimilarareemotions.so strongThethatflowtheyof i havpsycte " ing took place throughout the entire session, are difficult to repress, "The thoughts come so ' .' resul fast, before one is out, the other is there". Sex- thou: thomhe osexualsexual idcentityonflict wasor completefound in theconfusioncase his-in ual material is frequently noted and oft times tacul tory. A 21 year old Puerto Rican male with a forms the main part of the treatment session, psyc! history of marked homosexual conflict became It may be expressed openly or symbolically, studi panic stricken as he looked at the syringe used Inflating a blood pressure cuff reminded one ment to inject ehlorpromazine at the end of the treat- patient "of masturbation -- I masturbate with ment. This patient has been nauseous, retched, my right hand". Visual hallucinations are in- T vomited and expectorated throughout -_°-. frequent, although they occur more often in orde., Euphoria,expansiveness,and manic-likebe- the normal,psychoneurotica,rtistand writer. chost havior may appear. Emotions become more pro- Auditory hallucinations are reported but are line ; found, and the patient has a feeling of inner not frequent, preci awareness --the unkno_-n self that becomes The symptoms may rise and fall in waves, shoul apparent. He becomes the observer and the occasionally accompanied by nausea, and finally sion-? observed at the same time. Paranoid and recede after one hour, although they can re- easio somatic delusions, illusions, visual, auditory or main heightened up to the second hour. The atten olfactory hallucinations, depersonalization, de- symptoms slowly disappear, and by 4-6 hours exert realization, disturbances in perception of time are no longer present, ever: 24 I MESCALINE AND LSD: THERAPEUTIC IMPLICATIONS tp- Prolonged reactionscan occur23,and two psychoticbreakdown.This refersequallywell tic occurred in this present series. These were to the "fringe group" living a communal ex- ;x- probably the result of the patient's difficulty istence using excessive amounts of alcohol, It in coping with the flood of traumatic mater'al marijuana, cocaine, heroin, mescaline, lysergic n" which otherwise was repressed. It is im- acid diethylamide, amphetamine, etc., to sus- probable that they have a biochemical basis, at tain a failing ego. The drugs should not be ;ry . least if animal data can be extrapolated. The given to patients with paranoid personalities. _st concentration of mescaline in rat brain at two Cardiac disorders and hypertension may be ac- na hours is 0.004% of the amount injected in- centuated with mescaline. en itially :4. This amount is incapable of producing Technique ,er any reaction when given as a single dose. " The isolated use of mescaline and/or ly- .gs _ Indications sergic acid diethylamide cannot be considered _ry _ Mescaline or lysergic acid diethylamide are as a form of treatment. The drug session should ,trem, _5 " of value in the psvchoneuroses that are un- be conducted in a psychodynamic frame of re- re- _ responsive to psychotherapy or chemotherapy, ference by a psychiatrist experienced in the _a - They would be appropriate for use in those use of these agents, who has had a didactic at- cases where the psychoanalysis is at a stand- analysis, and who preferably has taken either _r- still andno therapeutic work seems possible for one personally.
Load more

Recommended publications
  • Peakal: Protons I Have Known and Loved — Fifty Shades of Grey-Market Spectra
    PeakAL: Protons I Have Known and Loved — Fifty shades of grey-market spectra Stephen J. Chapman* and Arabo A. Avanes * Correspondence to: Isomer Design, 4103-210 Victoria St, Toronto, ON, M5B 2R3, Canada. E-mail: [email protected] 1H NMR spectra of 28 alleged psychedelic phenylethanamines from 15 grey-market internet vendors across North America and Europe were acquired and compared. Members from each of the principal phenylethanamine families were analyzed: eleven para- substituted 2,5-dimethoxyphenylethanamines (the 2C and 2C-T series); four para-substituted 3,5-dimethoxyphenylethanamines (mescaline analogues); two β-substituted phenylethanamines; and ten N-substituted phenylethanamines with a 2-methoxybenzyl (NBOMe), 2-hydroxybenzyl (NBOH), or 2,3-methylenedioxybenzyl (NBMD) amine moiety. 1H NMR spectra for some of these compounds have not been previously reported to our knowledge. Others have reported on the composition of “mystery pills,” single-dose formulations obtained from retail shops and websites. We believe this is the first published survey of bulk “research chemicals” marketed and sold as such. Only one analyte was unequivocally misrepresented. This collection of experimentally uniform spectra may help forensic and harm-reduction organizations identify these compounds, some of which appear only sporadically. The complete spectra are provided as supplementary data.[1] Keywords: 1H NMR, drug checking, grey markets, research chemicals, phenylethanamines, N-benzyl phenylethanamines, PiHKAL DOI: http://dx.doi.org/10.16889/isomerdesign-1 Published: 1 August 2015 Version: 1.03 “Once you get a serious spectrum collection, Nevertheless, an inherent weakness of grey markets is the the tendency is to push it as far as you can.”1 absence of regulatory oversight.
    [Show full text]
  • From Sacred Plants to Psychotherapy
    From Sacred Plants to Psychotherapy: The History and Re-Emergence of Psychedelics in Medicine By Dr. Ben Sessa ‘The rejection of any source of evidence is always treason to that ultimate rationalism which urges forward science and philosophy alike’ - Alfred North Whitehead Introduction: What exactly is it that fascinates people about the psychedelic drugs? And how can we best define them? 1. Most psychiatrists will define psychedelics as those drugs that cause an acute confusional state. They bring about profound alterations in consciousness and may induce perceptual distortions as part of an organic psychosis. 2. Another definition for these substances may come from the cross-cultural dimension. In this context psychedelic drugs may be recognised as ceremonial religious tools, used by some non-Western cultures in order to communicate with the spiritual world. 3. For many lay people the psychedelic drugs are little more than illegal and dangerous drugs of abuse – addictive compounds, not to be distinguished from cocaine and heroin, which are only understood to be destructive - the cause of an individual, if not society’s, destruction. 4. But two final definitions for psychedelic drugs – and those that I would like the reader to have considered by the end of this article – is that the class of drugs defined as psychedelic, can be: a) Useful and safe medical treatments. Tools that as adjuncts to psychotherapy can be used to alleviate the symptoms and course of many mental illnesses, and 1 b) Vital research tools with which to better our understanding of the brain and the nature of consciousness. Classifying psychedelic drugs: 1,2 The drugs that are often described as the ‘classical’ psychedelics include LSD-25 (Lysergic Diethylamide), Mescaline (3,4,5- trimethoxyphenylathylamine), Psilocybin (4-hydroxy-N,N-dimethyltryptamine) and DMT (dimethyltryptamine).
    [Show full text]
  • Download Product Insert (PDF)
    Product Information Escaline (hydrochloride) Item No. 14107 CAS Registry No.: 3166-82-3 Formal Name: 4-ethoxy-3,5-dimethoxy- O NH2 benzeneethanamine, monohydrochloride Synonym: 4-ethoxy Mescaline MF: • HCl C12H19NO3 • HCl O FW: 261.7 Purity: ≥98% O Stability: ≥2 years at -20°C Supplied as: A crystalline solid Laboratory Procedures For long term storage, we suggest that escaline (hydrochloride) be stored as supplied at -20°C. It should be stable for at least two years. Escaline (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the escaline (hydrochloride) in the solvent of choice. Escaline (hydrochloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of escaline (hydrochloride) in these solvents is approximately 10, 3, 0.5 mg/ml, respectively. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of escaline (hydrochloride) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of escaline (hydrochloride) in PBS, pH 7.2, is approximately 3 mg/ml. We do not recommend storing the aqueous solution for more than one day. Escaline is the phenethylamine analog of 3C-E and the 4-ethoxy analog of mescaline. Its agonist activity at the serotonin 1 5-HT2A receptor is 5-8 times greater than mescaline.
    [Show full text]
  • Near the Himalayas, from Kashmir to Sikkim, at Altitudes the Catholic Inquisition, and the Traditional Use of These of up to 2700 Meters
    Year of edition: 2018 Authors of the text: Marc Aixalà & José Carlos Bouso Edition: Alex Verdaguer | Genís Oña | Kiko Castellanos Illustrations: Alba Teixidor EU Project: New Approaches in Harm Reduction Policies and Practices (NAHRPP) Special thanks to collaborators Alejandro Ponce (in Peyote report) and Eduardo Carchedi (in Kambó report). TECHNICAL REPORT ON PSYCHOACTIVE ETHNOBOTANICALS Volumes I - II - III ICEERS International Center for Ethnobotanical Education Research and Service INDEX SALVIA DIVINORUM 7 AMANITA MUSCARIA 13 DATURA STRAMONIUM 19 KRATOM 23 PEYOTE 29 BUFO ALVARIUS 37 PSILOCYBIN MUSHROOMS 43 IPOMOEA VIOLACEA 51 AYAHUASCA 57 IBOGA 67 KAMBÓ 73 SAN PEDRO 79 6 SALVIA DIVINORUM SALVIA DIVINORUM The effects of the Hierba Pastora have been used by Mazatec Indians since ancient times to treat diseases and for divinatory purposes. The psychoactive compound Salvia divinorum contains, Salvinorin A, is the most potent naturally occurring psychoactive substance known. BASIC INFO Ska Pastora has been used in divination and healing Salvia divinorum is a perennial plant native to the Maza- rituals, similar to psilocybin mushrooms. Maria Sabina tec areas of the Sierra Madre Oriental Mountains of Mexi- told Wasson and Hofmann (the discoverers of its Mazatec co. Its habitat is tropical forests, where it grows between usage) that Salvia divinorum was used in times when the- 300 and 800 meters above sea level. It belongs to the re was a shortage of mushrooms. Some sources that have Lamiaceae family, and is mainly reproduced by cuttings done later feldwork point out that the use of S. divinorum since it rarely produces seeds. may be more widespread than originally believed, even in times when mushrooms were abundant.
    [Show full text]
  • Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
    Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209
    [Show full text]
  • Hallucinogens: an Update
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Hallucinogens: An Update 146 U.S. Department of Health and Human Services • Public Health Service • National Institutes of Health Hallucinogens: An Update Editors: Geraline C. Lin, Ph.D. National Institute on Drug Abuse Richard A. Glennon, Ph.D. Virginia Commonwealth University NIDA Research Monograph 146 1994 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGEMENT This monograph is based on the papers from a technical review on “Hallucinogens: An Update” held on July 13-14, 1992. The review meeting was sponsored by the National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company.
    [Show full text]
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
    [Show full text]
  • 212102Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 212102Orig1s000 OTHER REVIEW(S) Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research | Office of Surveillance and Epidemiology (OSE) Epidemiology: ARIA Sufficiency Date: June 29, 2020 Reviewer: Silvia Perez-Vilar, PharmD, PhD Division of Epidemiology I Team Leader: Kira Leishear, PhD, MS Division of Epidemiology I Division Director: CAPT Sukhminder K. Sandhu, PhD, MPH, MS Division of Epidemiology I Subject: ARIA Sufficiency Memo for Fenfluramine-associated Valvular Heart Disease and Pulmonary Arterial Hypertension Drug Name(s): FINTEPLA (Fenfluramine hydrochloride, ZX008) Application Type/Number: NDA 212102 Submission Number: 212102/01 Applicant/sponsor: Zogenix, Inc. OSE RCM #: 2020-953 The original ARIA memo was dated June 23, 2020. This version, dated June 29, 2020, was amended to include “Assess a known serious risk” as FDAAA purpose (per Section 505(o)(3)(B)) to make it consistent with the approved labeling. The PMR development template refers to the original memo, dated June 23, 2020. Page 1 of 13 Reference ID: 46331494640015 EXECUTIVE SUMMARY (place “X” in appropriate boxes) Memo type -Initial -Interim -Final X X Source of safety concern -Peri-approval X X -Post-approval Is ARIA sufficient to help characterize the safety concern? Safety outcome Valvular Pulmonary heart arterial disease hypertension (VHD) (PAH) -Yes -No X X If “No”, please identify the area(s) of concern. -Surveillance or Study Population X X -Exposure -Outcome(s) of Interest X X -Covariate(s) of Interest X X -Surveillance Design/Analytic Tools Page 2 of 13 Reference ID: 46331494640015 1.
    [Show full text]
  • Neuroendocrine and Cardiovascular Effects of MDE in Healthy Volunteers
    NEUlIOPSYCHOPHARMACOLOGY 1993-VOL. 8, NO.3 187 Neuroendocrine and Cardiovascular Effects of MDE in Healthy Volunteers Euphrosyne Gouzoulis, M.D., Ulrich von Bardeleben, M.D., Armin Rupp, KIlrl-Arthur Kovar, Ph.D., and Leopold HermIe, M.D. Thedrug 3,4-methylenedioxyethamphetamine ([MDE] every 20 minutes until 5:00 P.M. Administration of also known as "Eve") is a less toxic analog of 3,4- MDE was followed by statistically significant long-lasting mtthylenedioxymethamphetamine (also known as increases of serum cortisol, PRL, systolic blood pressure, "Ecstasy") with similar psychotropic effects in humans. and heart rate, and by a trend toward blunting of GH In a double-blind placebo-controlled, cross-over study we secretion. The neuroendocrine and cardiovascular effects IIlministered 140 mg of MDE or placebo orally to eight of MDE are comparable to those of other phenethyl­ htaIthy male volunteers at 1:30 P.M. Serum cortisol, amines with the exception of the effect on GH secretion. prolactin (PRL), and growth hormone (GH) levels, as lNeuropsychopharmacology 8: 187-193, 1993J wellas blood pressure, and heart rate were measured KEY WORDS: MDE; MDMA; Cortisol; Prolactin; out distortion of sensory perception and thought and Growth honnone; Cardiovascular effects without marked stimulation (Greer and Tolbert 1986, 1990; Peroutka et al. 1988). Pharmacologic studies on The phenethylamines 3,4-methylenedioxymetham­ the structure-activity relationships of MDMA and phetamine ([MDMA]also known as "Ecstasy") and 3,4- related compounds supported the view that MDMA methylenedioxyethamphetamine ([MDE] also known and MDE might constitute a new psychoactive sub­ as"Eve") are chemically related to amphetamines and stance class, which was named the "entactogens" psychedelics like mescaline and methylenedioxyam­ (Nichols 1986; Nichols and Oberlender 1990).
    [Show full text]
  • Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans
    molecules Review Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans Paul Cumming 1,2,* , Milan Scheidegger 3 , Dario Dornbierer 3, Mikael Palner 4,5,6 , Boris B. Quednow 3,7 and Chantal Martin-Soelch 8 1 Department of Nuclear Medicine, Bern University Hospital, CH-3010 Bern, Switzerland 2 School of Psychology and Counselling, Queensland University of Technology, Brisbane 4059, Australia 3 Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital of the University of Zurich, CH-8032 Zurich, Switzerland; [email protected] (M.S.); [email protected] (D.D.); [email protected] (B.B.Q.) 4 Odense Department of Clinical Research, University of Southern Denmark, DK-5000 Odense, Denmark; [email protected] 5 Department of Nuclear Medicine, Odense University Hospital, DK-5000 Odense, Denmark 6 Neurobiology Research Unit, Copenhagen University Hospital, DK-2100 Copenhagen, Denmark 7 Neuroscience Center Zurich, University of Zurich and Swiss Federal Institute of Technology Zurich, CH-8058 Zurich, Switzerland 8 Department of Psychology, University of Fribourg, CH-1700 Fribourg, Switzerland; [email protected] * Correspondence: [email protected] or [email protected] Abstract: Hallucinogens are a loosely defined group of compounds including LSD, N,N- dimethyltryptamines, mescaline, psilocybin/psilocin, and 2,5-dimethoxy-4-methamphetamine (DOM), Citation: Cumming, P.; Scheidegger, which can evoke intense visual and emotional experiences. We are witnessing a renaissance of re- M.; Dornbierer, D.; Palner, M.; search interest in hallucinogens, driven by increasing awareness of their psychotherapeutic potential. Quednow, B.B.; Martin-Soelch, C. As such, we now present a narrative review of the literature on hallucinogen binding in vitro and Molecular and Functional Imaging ex vivo, and the various molecular imaging studies with positron emission tomography (PET) or Studies of Psychedelic Drug Action in single photon emission computer tomography (SPECT).
    [Show full text]
  • Sex Differences in Serotonergic and Dopaminergic Mediation of LSD Discrimination in Rats
    Western Michigan University ScholarWorks at WMU Dissertations Graduate College 8-2017 Sex Differences in Serotonergic and Dopaminergic Mediation of LSD Discrimination in Rats Keli A. Herr Western Michigan University, [email protected] Follow this and additional works at: https://scholarworks.wmich.edu/dissertations Part of the Psychology Commons Recommended Citation Herr, Keli A., "Sex Differences in Serotonergic and Dopaminergic Mediation of LSD Discrimination in Rats" (2017). Dissertations. 3170. https://scholarworks.wmich.edu/dissertations/3170 This Dissertation-Open Access is brought to you for free and open access by the Graduate College at ScholarWorks at WMU. It has been accepted for inclusion in Dissertations by an authorized administrator of ScholarWorks at WMU. For more information, please contact [email protected]. SEX DIFFERENCES IN SEROTONERGIC AND DOPAMINERGIC MEDIATION OF LSD DISCRIMINATION IN RATS by Keli A Herr A dissertation submitted to the Graduate College in partial fulfillment of the requirements for the degree of Doctor of Philosophy Psychology Western Michigan University August 2017 Doctoral Committee: Lisa Baker, Ph.D., Chair Cynthia Pietras, Ph.D. Heather McGee, Ph.D. Missy Peet, Ph.D. SEX DIFFERENCES IN SEROTONERGIC AND DOPAMINERGIC MEDIATION OF LSD DISCRIMINATION IN RATS Keli A. Herr, Ph.D. Western Michigan University After decades of opposition, a resurgence of interest in the psychotherapeutic potential of LSD is gaining acceptance in the medical community. Future acceptance of LSD as a psychotherapeutic adjuvant may be predicated on knowledge about its neural mechanisms of action. Preclinical drug discrimination assay offers an invaluable model to determine the neural mechanisms underlying LSD’s interoceptive stimulus effects.
    [Show full text]
  • Psychedelic Drugs
    108 PSYCHEDELIC DRUGS HENRY DAVID ABRAHAM UNA D. MCCANN GEORGE A. RICAURTE As defined in this chapter, the term psychedelic drugs includes 14.1%, and 7.2% of Danes reported the use of hallucino- both classic hallucinogens [i.e., indolalkylamines and phe- genic mushrooms (3). nylalkylamines, such as lysergic acid diethylamide (LSD) and In the United States, a survey of 633 undergraduates mescaline, respectively], ‘‘dissociative’’ drugs [i.e., arylcyclo- found that 23.8% had experimented with hallucinogenic hexamines, such as phencyclidine (PCP) and ketamine], and mushrooms, and 16.3% had had experience with LSD. substituted amphetamine analogues [i.e., phenylpropano- Among LSD users, 6.6% reported problems associated with lamines, such as 3,4-methylenedioxymethamphetamine LSD (Abraham and Koob, unpublished data). Of this group, (MDMA, ‘‘ecstasy’’)]. The use of psychedelic drugs dates 46.9% reported symptoms of hallucinogen persisting per- from the dawn of recorded history and continues today. ception disorder (HPPD), 37.5% described alcohol depen- Indeed, in Western culture, their use appears to be on the dence, 25% major depression, 18.8% persisting delusions, rise. Despite the longstanding popularity of psychedelic 15.6% panic attacks, and 12.5% auditory hallucinations. drugs, controlled research evaluating their effects in humans LSD use is most likely to occur between the ages of 18 and has been surprisingly scant, and data from preclinical studies 25. Use is more common in male Caucasians and Hispanics. have been largely limited to the last several decades. This Of note is that although the parents of LSD users tend to chapter reviews preclinical and clinical research involving be of a higher socioeconomic status, the users themselves indolalkylamines, arylcyclohexamines, and substituted am- exhibit an inverse relationship between LSD use and educa- phetamines, for which LSD, PCP, and MDMA are used as tional achievement (4).
    [Show full text]